210 related articles for article (PubMed ID: 22253746)
1. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
Shah M; Huang D; Blick T; Connor A; Reiter LA; Hardink JR; Lynch CC; Waltham M; Thompson EW
PLoS One; 2012; 7(1):e29615. PubMed ID: 22253746
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
[TBL] [Abstract][Full Text] [Related]
3. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
[TBL] [Abstract][Full Text] [Related]
4. Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells.
Liu B; Cui J; Sun J; Li J; Han X; Guo J; Yi M; Amizuka N; Xu X; Li M
Mol Med Rep; 2016 Aug; 14(2):1099-106. PubMed ID: 27278284
[TBL] [Abstract][Full Text] [Related]
5. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.
Peramuhendige P; Marino S; Bishop RT; de Ridder D; Khogeer A; Baldini I; Capulli M; Rucci N; Idris AI
Sci Rep; 2018 Jan; 8(1):39. PubMed ID: 29311633
[TBL] [Abstract][Full Text] [Related]
6. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Zannettino AC; Findlay DM; Evdokiou A
Mol Cancer Ther; 2009 Oct; 8(10):2969-80. PubMed ID: 19808976
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
10. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
Weber MH; Lee J; Orr FW
Int J Oncol; 2002 Feb; 20(2):299-303. PubMed ID: 11788892
[TBL] [Abstract][Full Text] [Related]
11. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
12. Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: real-time PCR quantitation.
Tester AM; Sharp JA; Dhanesuan N; Waltham M; Thompson EW
Clin Exp Metastasis; 2002; 19(5):377-83. PubMed ID: 12198765
[TBL] [Abstract][Full Text] [Related]
13. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice.
Lee J; Weber M; Mejia S; Bone E; Watson P; Orr W
Eur J Cancer; 2001 Jan; 37(1):106-13. PubMed ID: 11165137
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
15. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
Hu F; Wang C; Guo S; Sun W; Mi D; Gao Y; Zhang J; Zhu T; Yang S
Biochim Biophys Acta; 2011 Mar; 1809(3):200-10. PubMed ID: 21241837
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
17. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.
Nickerson NK; Mohammad KS; Gilmore JL; Crismore E; Bruzzaniti A; Guise TA; Foley J
PLoS One; 2012; 7(1):e30255. PubMed ID: 22276166
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin E3 ligase WWP1 decreases CXCL12-mediated MDA231 breast cancer cell migration and bone metastasis.
Subik K; Shu L; Wu C; Liang Q; Hicks D; Boyce B; Schiffhauer L; Chen D; Chen C; Tang P; Xing L
Bone; 2012 Apr; 50(4):813-23. PubMed ID: 22266093
[TBL] [Abstract][Full Text] [Related]
19. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Jones MD; Liu JC; Barthel TK; Hussain S; Lovria E; Cheng D; Schoonmaker JA; Mulay S; Ayers DC; Bouxsein ML; Stein GS; Mukherjee S; Lian JB
Clin Cancer Res; 2010 Oct; 16(20):4978-89. PubMed ID: 20843837
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells.
Ibaragi S; Shimo T; Iwamoto M; Hassan NM; Kodama S; Isowa S; Sasaki A
Anticancer Res; 2010 Dec; 30(12):5029-36. PubMed ID: 21187486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
